Use of recombinant GM-CSF following allogeneic BMTs for aplastic anemia

L. Chap, G. Schiller, Stephen D Nimer

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

GM-CSF has been used successfully in autologous BMTs, and more recently in patients undergoing allogeneic BMT, for acute or chronic leukemia. We report two patients with hepatitis-related aplastic anemia who received recombinant human GM-CSF following HLA-identical sibling allogeneic BMTs. Both patients were conditioned with CY 200 mg/kg given over 4 days and received GM-CSF at 250 μg/m2 beginning 6 h after marrow infusion and continuing daily until the absolute neutrophil count was > 1.0 X 109/l for 2 days. Both patients had prompt engraftment, achieving an absolute neutrophil count of > 0.5 X 109/l on day 13. Neither patient had side-effects attributable to the GM-CSF although one patient developed severe acute GVHD after the cessation of GM-CSF therapy. Our experience suggests that GM-CSF can be safely used in aplastic anemia patients undergoing BMT and that GM-CSF may be useful to decrease the incidence of graft failure associated with less intensive conditioning regimens.

Original languageEnglish
Pages (from-to)173-175
Number of pages3
JournalBone Marrow Transplantation
Volume12
Issue number2
StatePublished - Jan 1 1993
Externally publishedYes

Fingerprint

Aplastic Anemia
Granulocyte-Macrophage Colony-Stimulating Factor
Neutrophils
Hepatitis
Siblings
Leukemia
Bone Marrow
Transplants
Incidence

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Use of recombinant GM-CSF following allogeneic BMTs for aplastic anemia. / Chap, L.; Schiller, G.; Nimer, Stephen D.

In: Bone Marrow Transplantation, Vol. 12, No. 2, 01.01.1993, p. 173-175.

Research output: Contribution to journalArticle

@article{5dc17fd2be6341ca921b47955520ca05,
title = "Use of recombinant GM-CSF following allogeneic BMTs for aplastic anemia",
abstract = "GM-CSF has been used successfully in autologous BMTs, and more recently in patients undergoing allogeneic BMT, for acute or chronic leukemia. We report two patients with hepatitis-related aplastic anemia who received recombinant human GM-CSF following HLA-identical sibling allogeneic BMTs. Both patients were conditioned with CY 200 mg/kg given over 4 days and received GM-CSF at 250 μg/m2 beginning 6 h after marrow infusion and continuing daily until the absolute neutrophil count was > 1.0 X 109/l for 2 days. Both patients had prompt engraftment, achieving an absolute neutrophil count of > 0.5 X 109/l on day 13. Neither patient had side-effects attributable to the GM-CSF although one patient developed severe acute GVHD after the cessation of GM-CSF therapy. Our experience suggests that GM-CSF can be safely used in aplastic anemia patients undergoing BMT and that GM-CSF may be useful to decrease the incidence of graft failure associated with less intensive conditioning regimens.",
author = "L. Chap and G. Schiller and Nimer, {Stephen D}",
year = "1993",
month = "1",
day = "1",
language = "English",
volume = "12",
pages = "173--175",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Use of recombinant GM-CSF following allogeneic BMTs for aplastic anemia

AU - Chap, L.

AU - Schiller, G.

AU - Nimer, Stephen D

PY - 1993/1/1

Y1 - 1993/1/1

N2 - GM-CSF has been used successfully in autologous BMTs, and more recently in patients undergoing allogeneic BMT, for acute or chronic leukemia. We report two patients with hepatitis-related aplastic anemia who received recombinant human GM-CSF following HLA-identical sibling allogeneic BMTs. Both patients were conditioned with CY 200 mg/kg given over 4 days and received GM-CSF at 250 μg/m2 beginning 6 h after marrow infusion and continuing daily until the absolute neutrophil count was > 1.0 X 109/l for 2 days. Both patients had prompt engraftment, achieving an absolute neutrophil count of > 0.5 X 109/l on day 13. Neither patient had side-effects attributable to the GM-CSF although one patient developed severe acute GVHD after the cessation of GM-CSF therapy. Our experience suggests that GM-CSF can be safely used in aplastic anemia patients undergoing BMT and that GM-CSF may be useful to decrease the incidence of graft failure associated with less intensive conditioning regimens.

AB - GM-CSF has been used successfully in autologous BMTs, and more recently in patients undergoing allogeneic BMT, for acute or chronic leukemia. We report two patients with hepatitis-related aplastic anemia who received recombinant human GM-CSF following HLA-identical sibling allogeneic BMTs. Both patients were conditioned with CY 200 mg/kg given over 4 days and received GM-CSF at 250 μg/m2 beginning 6 h after marrow infusion and continuing daily until the absolute neutrophil count was > 1.0 X 109/l for 2 days. Both patients had prompt engraftment, achieving an absolute neutrophil count of > 0.5 X 109/l on day 13. Neither patient had side-effects attributable to the GM-CSF although one patient developed severe acute GVHD after the cessation of GM-CSF therapy. Our experience suggests that GM-CSF can be safely used in aplastic anemia patients undergoing BMT and that GM-CSF may be useful to decrease the incidence of graft failure associated with less intensive conditioning regimens.

UR - http://www.scopus.com/inward/record.url?scp=0027235740&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027235740&partnerID=8YFLogxK

M3 - Article

C2 - 8401368

AN - SCOPUS:0027235740

VL - 12

SP - 173

EP - 175

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 2

ER -